Rinvoq Archives -

AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The

AbbVie and Cugene partner to tackle autoimmune diseases

https://pharmaphorum.com/news/abbvie-and-cugene-partner-to-tackle-autoimmune-diseases/

AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

https://pharmaphorum.com/news/third-positive-trial-sets-up-filings-for-abbvies-rinvoq-in-crohns/

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA

Leo puts target on Dupixent in US as FDA clears tralokinumab

https://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/

The FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings

FDA firms up JAK inhibitor warnings after Xeljanz review

https://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/

The FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has

AbbVie’s Rinvoq cleared in EU for atopic dermatitis

https://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/

The FDA has said it will wait for additional results from last week’s trial showing an increased risk

FDA holds back from action over Xeljanz safety study

https://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and

Bad news for Pfizer as blockbuster Xeljanz flunks safety study

https://pharmaphorum.com/news/bad-news-for-pfizer-as-blockbuster-xeljanz-flunks-safety-study/

Rinvoq